Current evidence suggests that the MSI-H phenotype in patients with sporadic GC is closely associated with hypermethylation of the promoter CpG island causing silencing of the hMLH1 gene, which leads to progressive loss of MLH1 protein expression [31–33]. The gene discussed is MLH1; the disease is gastric cancer.